An online survey of mycology laboratories in seven Asian countries was conducted to assess the status, competence, and services available. Country representatives from the Asia Fungal Working Group (AFWG) contacted as many laboratories performing mycology diagnosis as possible in their respective countries, requesting that the laboratory heads complete the online survey. In total, 241 laboratories responded, including 71 in China, 104 in India, 11 in Indonesia, 26 Chindamporn et al.
Introduction
Asia has the largest burden of fungal disease in the world when one considers that more than half the world's population lives in the region. The tropical environment in a large portion of the region, inadequately trained healthcare professionals, misuse or abuse of steroids and broadspectrum antibiotics, and compromised healthcare practices due to over-capacity patient loads in public sector hospitals are major concerns and may contribute to the high burden of fungal infections in Asia. [1] [2] [3] [4] [5] In addition, many
Asian countries lack high-quality mycology laboratories, and awareness of fungal diseases is limited. To overcome the challenges and achieve discernible change in morbidity and mortality due to fungal infections, the Asia Fungal Working Group (AFWG) was formed under the auspices of the International Society for Human and Animal Mycology (ISHAM). The aim of the AFWG is to improve patient care by advancing the diagnosis and management of fungal infections. The AFWG performed a gap analysis of mycology laboratories in seven Asian countries through an online survey conducted during the second half of 2016. This manuscript provides a comprehensive analysis of the survey results to describe the present status of mycology diagnostic services in seven Asian countries.
Method
In February 2016, the AFWG planned an online survey to assess the competencies of mycology laboratories in seven Asian countries in which the AFWG board has a country representative. A 36-item questionnaire was developed covering laboratory structure, equipment, manpower, personnel training, and diagnostic testing availability and frequency of use (See Supplement 1 for the survey questionnaire). AFWG country representatives were responsible for recruiting respondents for the survey in their respective countries. As no data were available on the total number of laboratories performing fungal diagnosis in each country, the goal was to recruit at least 100 randomly chosen laboratories in both China and India that performed diagnosis of fungal infections. For the other five countries, attempts were made to recruit laboratories from all medical teaching institutes. The AFWG country representatives tried to achieve this target through their personal contacts with heads of laboratories in their respective countries or used the Facebook pages or websites of relevant societies to send an appeal for laboratories performing fungal diagnosis to participate in the online survey.
Data analysis
A professional consulting firm programmed and hosted the online survey, and was responsible for data capture from the participating laboratories. The data sets were scrutinized for missing or discrepant data; discrepant data were excluded, and attempts were made to resolve incomplete responses by contacting the relevant laboratory. Finally, the authors analyzed the data, using the Marascuilo procedure for between-country comparisons. The Marascuilo procedure, an extension of the χ 2 test, is a parametric test used for multiple comparisons of proportions that can identify the data points responsible for rejection of the null hypothesis (i.e., all proportions considered equal) in the overall χ 2 test. The level for statistical significance was set at <0.05 for any data comparisons.
Results
The number of laboratories approached individually in each country included India (n = 164), Indonesia (n = 182), Singapore (n = 6), Taiwan (n = 21), and Thailand (n = 14). In China, an invitation was sent through the medical mycology Web net, comprising nearly 500 people; in the Philippines, an invitation was posted on the Pathology Society Facebook Group page, with an unspecified number of members in the group. Overall, 241 laboratories from seven countries participated (in rank order): India (n = 104), China (n = 71), the Philippines (n = 26), Taiwan (n = 18), Indonesia (n = 11), Thailand (n = 7), and Singapore (n = 4). Responses were compiled by country and the data analyzed; results are presented in Tables 1 and 2 . As the number of laboratories responding to each survey question varied, the respondent number (base) is specified for each country at each question (Tables 1 and 2 ). Figure 1 shows the location of the participating laboratories on a regional map.
Laboratory structure
Overall, 129/241 (53.5%) mycology diagnostic areas function as independent mycology laboratories, meaning they are stand-alone mycology laboratories with separate laboratory space and manpower ( 
Cryptococcus antigen tests used: 
Conventional diagnosis and identification of fungi
The vast majority (230/241, 95.4%) of laboratories participating in the survey perform direct microscopy of samples, while fluorescence microscopy with the calcofluor white or fluorescent brightener technique is available in 99/241 (41.1%) laboratories ( (Table 2) . Of the 142 laboratories that indicated they perform antifungal susceptibility testing, 139 specified for which pathogens the testing was performed. 
Serology
Of all surveyed laboratories, 77/241 (32%) indicated they perform serological/antigen testing. Of those performing Cryptococcus antigen detection testing (n = 66), 43 (66.2%) use the latex agglutination method, 4 (6.2%) use an enzyme-linked immunosorbent assay (ELISA) method, and 19 (29.2%) use a lateral flow assay (Table 2) . Only 6.6% (5/76) of laboratories that conduct serological/antigen testing perform Histoplasma antigen assays. Some form of Candida antigen testing is available in 18.2% (37/203) of laboratories. (1→3)-β-D-glucan (BDG) testing is available in 24 of 35 laboratories: 18 in China, four in India and one in Thailand. Five laboratories in China perform this test 5 times a week. Galactomannan antigen testing is available in 22.8% (55/241) of surveyed laboratories; it is most commonly performed 1-2 times weekly (21/32, 65.6%); two laboratories (one each in India and China) perform the test daily (i.e., 6 times weekly). Estimation of immunoglobulin E (IgE) (total or Aspergillusspecific) is available to 48 of the 77 laboratories who perform serological testing, either within the laboratory or in another laboratory within the same hospital. Twentyseven of these 48 laboratories specify that they perform total IgE estimation (7/13 in China, 14/23 in India, 4/7 in Taiwan, 1/1 in the Philippines, and 1/1 in Thailand), with six of these 27 (1/13 in China and 5/23 in India) indicating that they additionally perform Aspergillus-specific IgE estimations.
Molecular diagnosis and therapeutic drug monitoring for azoles
Of the 53/241 (22%) laboratories that indicated they have molecular diagnosis facilities, 37 perform polymerase chain reaction (PCR) for diagnosis of fungal infections (including 16/20 in China and 13/23 in India). Of those, 26/37 (70.3%) employ an in-house technique and 14/37 (37.8%) laboratories use commercial PCR diagnosis (manufacturer not specified) of fungal infections (Table 2) . However, in our survey, respondents were not asked to specify whether PCR diagnosis was performed on a patient specimen or a fungal isolate. (Table 2) .
Discussion
The challenge posed by fungal infections is gaining importance worldwide, 6 especially in Asia. [1] [2] [3] [4] [5] The true burden of fungal infections in this region is largely unknown, and any data from developing countries are likely to be underestimates due to the absence of diagnostic mycology laboratories. The present study provides, despite certain limitations, a snapshot of the status of diagnostic mycology services in seven Asian countries. Despite our best efforts, we obtained responses from 104 and 71 laboratories in India and China, respectively, although these countries are vast in size and contain the largest populations of the world. The situation in Indonesia, the Philippines, and Thailand is no better, as we received responses from 11, 26, and 7 laboratories, respectively, in those countries.
There have been few attempts worldwide at conducting this type of survey to provide a status report on medical mycology services. [7] [8] [9] [10] Our survey is the maiden attempt in
Asia. Aside from a few laboratories in our survey, most laboratories lack continuing education and training in medical mycology. A special effort may be required in Indonesia as significantly fewer laboratories conducted formal training of laboratory staff than in other countries. The present survey identifies an urgent need to increase investment in mycology laboratories, especially to fund the incorporation of MALDI-TOF MS and non-culturebased biomarker tests like galactomannan, β-D-glucan and fungal PCR. The capital investment in MALDI-TOF MS may be high, but overall the procedure is cost-effective due to early identification, and reduced reagent and labor costs. 19 The situation appears worse in Indonesia, the Philippines, and Thailand, where those biomarker tests are nearly non-existent. The lack of facilities hinders epidemiological and outbreak investigations and compromises the management of patients with fungal infections in Asian countries. Biosafety in the laboratory is also an important issue. All laboratories performing fungal diagnosis should be equipped with biosafety hood. The study has certain limitations. We do not know the exact number of laboratories performing mycology diagnostic services in each country and, thus, what percentage of those laboratories participated in the survey from each country. There is an absence or lack of readily available support from government or non-government agencies on fungal diseases in all Asian countries. Reviewing the map of the countries and laboratories surveyed, it appears the study is well represented in India, the Philippines, and Singapore, but skewed in China, Indonesia, and Thailand. In addition, it is possible that there were some instances where survey respondents might have misunderstood the meaning of a question. To avoid including misleading data in the analysis set, we censored some clear outlier responses from the database, for example, responses to the bed count of the catchment area of the laboratory. Still, the present study is the first serious attempt to develop a status report of diagnostic mycology services in Asian countries.
An urgent concerted effort from government, academia, and other stakeholders is required to support the development of new quality mycology laboratories and the improvement of existing laboratories with regular staff training, accreditation, and inclusion of essential advanced rapid biomarker tests and equipment. Only then we will have the tools and skills in place to curb the morbidity and mortality of invasive fungal diseases in the Asian population.
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